81 related articles for article (PubMed ID: 28371832)
1. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
[TBL] [Abstract][Full Text] [Related]
3. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
[TBL] [Abstract][Full Text] [Related]
4. A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Desai PB; Karve AS; Zawit M; Arora P; Dave N; Awosika J; Li N; Fuhrman B; Medvedovic M; Sallans L; Kendler A; DasGupta B; Plas D; Curry R; Zuccarello M; Chaudhary R; Sengupta S; Wise-Draper TM
Clin Cancer Res; 2024 May; 30(10):2068-2077. PubMed ID: 38530160
[TBL] [Abstract][Full Text] [Related]
5. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
van den Bent M; Azaro A; De Vos F; Sepulveda J; Yung WKA; Wen PY; Lassman AB; Joerger M; Tabatabai G; Rodon J; Tiedt R; Zhao S; Kirsilae T; Cheng Y; Vicente S; Balbin OA; Zhang H; Wick W
J Neurooncol; 2020 Jan; 146(1):79-89. PubMed ID: 31776899
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of terameprocol in patients with recurrent high-grade glioma.
Grossman SA; Ye X; Peereboom D; Rosenfeld MR; Mikkelsen T; Supko JG; Desideri S;
Neuro Oncol; 2012 Apr; 14(4):511-7. PubMed ID: 22323663
[TBL] [Abstract][Full Text] [Related]
7. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R
Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907
[TBL] [Abstract][Full Text] [Related]
8. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY;
Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Fisher BJ; Pugh SL; Macdonald DR; Chakravatri A; Lesser GJ; Fox S; Rogers CL; Werner-Wasik M; Doyle T; Bahary JP; Fiveash JB; Bovi JA; Howard SP; Michael Yu HH; D'Souza D; Laack NN; Barani IJ; Kwok Y; Wahl DR; Strasser JF; Won M; Mehta MP
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):720-725. PubMed ID: 32251755
[TBL] [Abstract][Full Text] [Related]
11. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
12. Targetable T-type Calcium Channels Drive Glioblastoma.
Zhang Y; Cruickshanks N; Yuan F; Wang B; Pahuski M; Wulfkuhle J; Gallagher I; Koeppel AF; Hatef S; Papanicolas C; Lee J; Bar EE; Schiff D; Turner SD; Petricoin EF; Gray LS; Abounader R
Cancer Res; 2017 Jul; 77(13):3479-3490. PubMed ID: 28512247
[TBL] [Abstract][Full Text] [Related]
13. CD4
Borst J; Ahrends T; Bąbała N; Melief CJM; Kastenmüller W
Nat Rev Immunol; 2018 Oct; 18(10):635-647. PubMed ID: 30057419
[TBL] [Abstract][Full Text] [Related]
14. Regulation and Function of the PD-L1 Checkpoint.
Sun C; Mezzadra R; Schumacher TN
Immunity; 2018 Mar; 48(3):434-452. PubMed ID: 29562194
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E
J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790
[TBL] [Abstract][Full Text] [Related]
16. Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach.
Bayona C; Alza L; Ranđelović T; Sallán MC; Visa A; Cantí C; Ochoa I; Oliván S; Herreros J
Cell Death Dis; 2024 Feb; 15(2):127. PubMed ID: 38341408
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cells in brain tumors: From origin to clinical implications.
Lin S; Li K; Qi L
MedComm (2020); 2023 Aug; 4(4):e341. PubMed ID: 37576862
[TBL] [Abstract][Full Text] [Related]
18. Increased KCNN4 Expression Is Correlated With Poor Survival in Lower Grade Glioma.
Lehrer S; Rheinstein PH
Cancer Diagn Progn; 2023; 3(4):428-432. PubMed ID: 37405224
[TBL] [Abstract][Full Text] [Related]
19. Calcium signalling pathways in prostate cancer initiation and progression.
Silvestri R; Nicolì V; Gangadharannambiar P; Crea F; Bootman MD
Nat Rev Urol; 2023 Sep; 20(9):524-543. PubMed ID: 36964408
[TBL] [Abstract][Full Text] [Related]
20. T-Type Calcium Channels: A Mixed Blessing.
Melgari D; Frosio A; Calamaio S; Marzi GA; Pappone C; Rivolta I
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
